Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Immunomodulatory-therapies"

2 News Found

Shilpa Medicare signs long-term CDMO manufacturing deal with NXI Therapeutics
News | May 13, 2026

Shilpa Medicare signs long-term CDMO manufacturing deal with NXI Therapeutics

The partnership covers the entire product lifecycle from early-stage development through commercialization


Vyome secures exclusive license from Impetis for selective JAK inhibitor programs
News | May 13, 2026

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments